BlackRock Health Sciences Trust

The company holds $548 in cash, though total debt stands at $894K. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$2.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 13.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from -$26.0M (2022) to $77.5M (2025), reflecting a 399% increase over the period.

With a beta below 0.7, BlackRock Health Sciences Trust typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing BME's risk profile alongside its fundamentals and technical indicators provides a more complete picture.